



# Methodologies for Establishing the Relationship Between Alcohol/Drug Use and Driving Impairment — Differences Between Epidemiological, Experimental, and Real-Case Studies

H. Gjerde<sup>1\*</sup>, J. G. Ramaekers<sup>2</sup>, J. G. Mørland<sup>3,4</sup>

<sup>1</sup>Department of Forensic Sciences  
Oslo University Hospital  
Oslo, Norway

<sup>3</sup>Division of Health Data and Digitalization  
Norwegian Institute of Public Health  
Oslo, Norway

<sup>2</sup>Department of Neuropsychology and  
Psychopharmacology  
University of Maastricht  
Maastricht, The Netherlands

<sup>4</sup>Institute of Clinical Medicine  
University of Oslo  
Oslo, Norway

## TABLE OF CONTENTS

INTRODUCTION .....	142
I. EXPERIMENTAL STUDIES .....	142
A. Controlled Laboratory Studies .....	144
B. Driving Simulator Studies .....	144
C. On-the-Road Driving Studies .....	144
II. EPIDEMIOLOGICAL STUDIES .....	144
A. Pharmacoepidemiological Cohort Studies .....	146
B. Case-Crossover Studies .....	146
C. Case-Control Studies .....	147
D. Responsibility Studies .....	147
E. Meta-analyses and Systematic Reviews .....	148
III. REAL-CASE STUDIES .....	148
A. Drivers Arrested for Driving Under the Influence .....	148
B. Drivers Involved in Road Traffic Crashes .....	149
IV. DISAGREEMENTS BETWEEN STUDIES .....	149
A. Alcohol .....	149
B. Amphetamine and Methamphetamine .....	150
C. Cannabis .....	151
D. Diazepam .....	153
CONCLUSIONS .....	154
REFERENCES .....	154
ABOUT THE AUTHORS .....	159

\* Corresponding author: Dr. H. Gjerde, Department of Forensic Sciences, Oslo University Hospital, PO Box 4950 Nydalen, N-0424 Oslo, Norway; + 47 23013045 (voice); [rmhage@ous-hf.no](mailto:rmhage@ous-hf.no).

# Methodologies for Establishing the Relationship Between Alcohol/Drug Use and Driving Impairment – Differences Between Epidemiological, Experimental, and Real-Case Studies

**REFERENCE:** Gjerde H, Ramaekers JG, Mørland JG: Methodologies for establishing the relationship between alcohol/drug use and driving impairment — Differences between epidemiological, experimental, and real-case studies; *Forensic Sci Rev* 31:141; 2019.

**ABSTRACT:** Experimental, epidemiological, and real-case studies have different advantages and limitations when used to study the effect of substance use on the risk for involvement in a road traffic crash. It is easier to perform well-controlled experimental studies than well-controlled epidemiological studies, due to difficulties related to selection bias, information bias, and confounding. On the other hand, it is difficult or impossible to perform experimental studies using single and repeated substance doses similar to those used by drivers and problematic drugs users. Real-case studies indicate which substances may cause observed impairment and involvement in road traffic crashes and at which concentrations; however, those studies cannot be used to quantify crash risks or determine causality. All three types of studies are needed to obtain a broad and complete picture as they may complement each other when assessing the effects of substance use on road traffic safety.

**KEYWORDS:** Alcohol, drugs, impairment, research methods, road traffic crash, substance use, traffic safety.

## INTRODUCTION

A large proportion of road traffic crashes are caused by driver impairment after using alcohol or other psychoactive substances [167]. Analysis of blood samples from those arrested for driving under the influence (DUI) of alcohol or drugs, or from crash-involved drivers, show variations in detected substances across countries related to regional differences in the use of alcohol, recreational drugs, and psychoactive medicines, including problematic use and addiction, as well as differences in attitudes toward driving after using alcohol or drugs [21,47,94,95]. Such differences make comparison between studies difficult. In general, alcohol is the most commonly used psychoactive substance among drivers, followed by cannabis, central nervous stimulants such as amphetamines and cocaine, and central nervous depressants such as sedatives, hypnotics, and narcotic analgesics. Multiple substance use is also common among arrested DUI offenders [66,84,154].

Most countries have implemented statutory alcohol concentration limits in blood or breath for DUI of alcohol. Many countries also have laws on driving under the influence of drugs other than alcohol, which may either be based on documented impairment, zero tolerance for psychoactive drugs, or concentration per se limits in blood [21,162]. Zero-tolerance laws make it a criminal offense to have a drug or metabolite in the body while operating a motor vehicle, and is sometimes regarded as a type of per se legislation. This legal framework was constructed, at least in part, to simplify the evidence necessary for a successful prosecution [74].

Standardized research methods are needed in order to generate accurate and reproducible data when studying the effects of alcohol and drugs on the ability to drive safely. The first recommendations and guidelines were published in the 1980s and '90s [29,69,70,82]. In 2007, an expert meeting was held in Talloires (France) where guidelines on both experimental and epidemiological research were discussed [163]. As an outcome of that meeting, more detailed guidelines and recommendations were developed and published in 2008 [164]. US National Highway Traffic Safety Administration published a consensus protocol for assessing the potential of drugs to impair driving in 2011, although with less details [85], and a white paper on drugged-driving research was published by the Drugged Driving Committee of the Institute for Behavior and Health in the US, also in 2011 [33]. Finally, the Food and Drug Administration published Guidance for Industry on the evaluation of drug effects on the ability to operate a motor vehicle in 2017 [38], although less detailed than other guidelines.

The aim of this article is to describe the methodologies used to investigate the effect of alcohol and drugs on the ability to drive safely, present the main advantages and challenges, and discuss disagreements between findings for some substances.

## I. EXPERIMENTAL STUDIES

Experimental studies on the acute effects of alcohol and/or drugs on a person's ability to drive safely are performed by giving a defined amount of substance to a number of test persons and measuring the effect on performance at predefined time points.

148. Terhune KW: *The Role of Alcohol, Marijuana, and Other Drugs in the Accidents of Injured Drivers. Volume I—Findings* (DOT HS 806 199); US National Highway Traffic Safety Administration: Washington, DC; 1982.
149. Thomas RE: Benzodiazepine use and motor vehicle accidents. Systematic review of reported association; *Can Fam Physician* 44:799; 1998.
150. Tourangeau R, Yan T: Sensitive questions in surveys; *Psychol Bull* 133:859; 2007.
151. Traffic Injury Research Foundation: *Marijuana Use Among Drivers in Canada, 2000–2015*; Traffic Injury Research Foundation: Ottawa, Canada; 2018.
152. Traynor TL: The impact of driver alcohol use on crash severity: A crash specific analysis; *Transp Res Part E Logist Transp Rev* 41:421; 2005.
153. Valen A, Bogstrand ST, Vindenes V, Gjerde H: Increasing use of cannabis among arrested drivers in Norway; *Traffic Inj Prev* 18:801; 2017.
154. Valen A, Bogstrand ST, Vindenes V, Gjerde H: Toxicological findings in suspected drug-impaired drivers in Norway — Trends during 1990–2015; *Forensic Sci Int* 280:15; 2017.
155. Veldstra JL, Bosker WM, de Waard D, Ramaekers JG, Brookhuis KA: Comparing treatment effects of oral THC on simulated and on-the-road driving performance: Testing the validity of driving simulator drug research; *Psychopharmacology* (Berl) 232:2911; 2015.
156. Verster JC, Mets MA: Psychoactive medication and traffic safety; *Int J Environ Res Public Health* 6:1041; 2009.
157. Verster JC, Ramaekers JG: The on-the-road driving test; In Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ (Eds): *Drugs, Driving and Traffic Safety*; Birkhäuser Basel: Basel, Switzerland; p 83; 2009.
158. Verstraete AG: Detection times of drugs of abuse in blood, urine, and oral fluid; *The Drug Monit* 26:200; 2004.
159. Verstraete AG, Legrand SA, Vandam L, Hughes B, Griffiths B: *Drug Use, Impaired Driving, and Traffic Accidents*, 2nd ed; Publications Office of the European Union: Luxembourg; 2014.
160. Vindenes V, Jordbru D, Knapskog AB, Kvan E, Mathisrud G, Slørdal L, Mørland J: Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway; *Forensic Sci Int* 219:1; 2012.
161. Voas RB, Torres P, Romano E, Lacey JH: Alcohol-related risk of driver fatalities: An update using 2007 data; *J Stud Alcohol Drugs* 73:341; 2012.
162. Walsh JM, de Gier JJ, Christophersen AS, Verstraete AG: Drugs and driving; *Traffic Inj Prev* 5:241; 2004.
163. Walsh JM, Huestis MA, Mørland J: *Guidelines for Drugged Driving Research. The Talloires Report*; The Walsh Group: Bethesda, MD; 2007.
164. Walsh JM, Verstraete AG, Huestis MA, Mørland J: Guidelines for research on drugged driving; *Addiction* 103:1258; 2008.
165. Wetherell A: Performance tests; *Environ Health Perspect* 104 (Suppl 2):247; 1996.
166. Wood E, Brooks-Russell A, Drum P: Delays in DUI blood testing: Impact on cannabis DUI assessments; *Traffic Inj Prev* 17:105; 2016.
167. World Health Organization: *Global Status Report on Road Safety 2015*; World Health Organization: Geneva, Switzerland; 2015.
168. Zador PL, Krawchuk SA, Voas RB: Alcohol-related relative risk of driver fatalities and driver involvement in fatal crashes in relation to driver age and gender: An update using 1996 data; *J Stud Alcohol* 61:387; 2000.



**Hallvard Gjerde** obtained his M.Sc. degree in biochemistry from the University of Oslo (Oslo, Norway) in 1983 and a Ph.D. from the Faculty of Medicine of the same university in 1988. Dr. Gjerde is currently a senior researcher in the Department of Forensic Sciences, Oslo University Hospital (Oslo, Norway).

From 1983 to 1992, Dr. Gjerde was a researcher at the former Norwegian National Institute of Forensic Toxicology (Oslo, Norway). From 1992 to 2007 he specialized in pharmaceutical analysis for a private company. Since 2007, Dr. Gjerde has been a senior researcher at the Division of Forensic Sciences of the Norwegian Institute of Public Health (Oslo, Norway); the forensic science business was transferred to Oslo University Hospital in 2017.

Dr. Gjerde has published about 100 articles in peer-reviewed journals on drug analysis, forensic sciences, alcohol and drug use, and road traffic safety. He is currently a board member of the International Council of Alcohol, Drugs and Traffic Safety.

---

**Johannes (Jan) G. Ramaekers** studied psychology at University of Groningen (Groningen, The Netherlands) and received his master's degree in 1988. He defended his Ph.D. at Maastricht University (Maastricht, The Netherlands) on behavioral toxicity of medicinal drugs in 1998. Dr. Ramaekers is currently professor of psychopharmacology at the Faculty of Psychology & Neuroscience of Maastricht University.

Dr. Ramaekers's research focuses on effects of medicinal and illicit drugs on cognitive functions and driving. He has been organizing courses in the field of Human Psychopharmacology, Biological Psychology, and Traffic & Aviation Psychology and is the author or co-author of almost 200 peer-reviewed articles. He is currently president of the International Council of Alcohol, Drugs and Traffic Safety.

---

---

**Jørg G. Mørland** received an M.D. degree from the University of Oslo in 1967 and a Ph.D. degree in pharmacology from the same university in 1975. Dr. Mørland is now a senior scientist at the Division of Health Data and Digitalization of the Norwegian Institute of Public Health and a professor emeritus at the University of Oslo.

Throughout his professional career, Dr. Mørland has served as professor of pharmacology at the University of Oslo and the University of Tromsø (Tromsø, Norway), director of the former Norwegian National Institute of Forensic Toxicology, and director of the Division of Forensic Medicine and Drug Abuse Research of the Norwegian Institute of Public Health (Oslo, Norway) until 2012.

Dr. Mørland is a medical specialist in clinical pharmacology. His main research field is biomedical effects of alcohol and drugs of abuse, their metabolites and metabolism. He has been and is the principal supervisor for approximately 30 Ph.D. students, as well as being the scientific project manager for several projects supported by the Research Council of Norway.

Dr. Mørland has published more than 400 articles in peer-reviewed journals on pharmacology, toxicology, forensic sciences, neuroscience, alcoholism, epidemiology, drug analysis, and road traffic safety. He has also written more than 8,000 expert-witness statements for the police and courts in Norway, and has had several hundred court appearances as an expert witness in courts at all levels in Norway as well as in some courts in Sweden. He was the recipient of a Widmark Award from the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) in 2004.